PA
CRVS icon

Perceptive Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Perceptive Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.9M Buy
2,667,441
+375,000
+16% +$5.2M 0.6% 36
2026
Q1 		$33.5M Buy
2,292,441
+1,600,000
+231% +$25.5M 0.66% 35
2025
Q4 		$5.33M Sell
692,441
-746,154
-52% -$5.88M 0.1% 93
2025
Q3 		$10.6M Hold
1,438,595
– – 0.31% 55
2025
Q2 		$5.75M Buy
+1,438,595
New +$5.23M 0.21% 64

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Perceptive Advisors's CRVS Position: Q2 2026 in Review

Perceptive Advisors increased its Corvus Pharmaceuticals (CRVS) stake by 16% in Q2 2026, buying an estimated $5.2M and bringing the position to 2,667,441 shares worth $39.9M. The position accounts for 0.6% of the portfolio, ranked #36.

Perceptive Advisors first reported a position in CRVS in Q2 2025 and has held it in 5 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Perceptive Advisors held 2,667,441 shares of Corvus Pharmaceuticals worth $39.9M as of Q2 2026.
  • Perceptive Advisors bought 375,000 Corvus Pharmaceuticals shares in Q2 2026, an estimated $5.2M.
  • Corvus Pharmaceuticals made up 0.6% of Perceptive Advisors's portfolio in Q2 2026, its #36 holding.
  • Perceptive Advisors first reported a position in Corvus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.